Sarcoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 31 expanded access programs, clinical trials, and compassionate use pathways listed for Sarcoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with sarcoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 12 programs are currently active or recruiting, with the remaining 19 in other lifecycle stages. Sponsors actively running programs in this area include Memorial Sloan Kettering Cancer Center, City of Hope Medical Center, Sarcoma Oncology Research Center, LLC, Actuate Therapeutics Inc., Agenus Inc., and others.
By recruiting status
Snapshot of where every Sarcoma program currently sits in its lifecycle.
- Active / Recruiting12
- Inactive19
Top sponsors
Organisations running the most Sarcoma programs in the directory.
- Memorial Sloan Kettering Cancer Center8 programs
- City of Hope Medical Center2 programs
- Sarcoma Oncology Research Center, LLC2 programs
- Actuate Therapeutics Inc.1 program
- Agenus Inc.1 program
- Aveni Foundation1 program
- CivaTech Oncology1 program
- Cybrexa Therapeutics1 program
- David S Shulman, MD1 program
- EpicentRx, Inc.1 program
Sarcoma programs (31)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 9-ING-41 for Patients with Advanced Cancers — Actuate Therapeutics Inc.
- Study on Epacadostat and Pembrolizumab for Patients with Advanced Sarcoma — Memorial Sloan Kettering Cancer Center
- Study on Pembrolizumab for People with Very Rare Types of Sarcoma — Memorial Sloan Kettering Cancer Center
- Study on Talimogene Laherparepvec (T-VEC) and Pembrolizumab for Treating Advanced Sarcoma — Memorial Sloan Kettering Cancer Center
- Study on Using Fluorescence-Guided Surgery to Reduce Unexpected Positive Margins in Sarcoma Patients — City of Hope Medical Center
- Study on Irinotecan and Carboplatin as Initial Treatment for Newly Diagnosed Intermediate or High-Risk Rhabdomyosarcoma — Memorial Sloan Kettering Cancer Center
- Karyopharm Expanded Access Program for Selinexor — Karyopharm Therapeutics Inc
- Study on Retifanlimab with Gemcitabine and Docetaxel for Advanced Soft Tissue Sarcoma — Memorial Sloan Kettering Cancer Center
- Study on Abemaciclib for Treating Dedifferentiated Liposarcoma — Memorial Sloan Kettering Cancer Center
- Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients with Advanced Leiomyosarcoma — Gabriel Tinoco
- Study on Weekly Doxorubicin for Elderly Patients with Advanced or Metastatic Leiomyosarcoma — University of Colorado, Denver
- Study on Using Thermal Ablation and Precision Radiation for Treating Spine Cancer at Risk of Spinal Cord Compression — M.D. Anderson Cancer Center
- Study on Intratumoral T3011 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — ImmVira Pharma Co. Ltd
- Study on KVA12123 Treatment Alone and with Pembrolizumab for Advanced Solid Tumors (VISTA-101) — Kineta Inc.
- Study on AdAPT-001 for Patients with Sarcoma and Hard-to-Treat Solid Tumors — EpicentRx, Inc.
- Study on Cabozantinib to Prevent Progression or Return of High-Risk Pediatric Solid Tumors — Nationwide Children's Hospital
- A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma — Memorial Sloan Kettering Cancer Center
- Study of Pembrolizumab and Local Chemotherapy for Sarcoma in the Arm or Leg — Memorial Sloan Kettering Cancer Center
- Study on SNS-101 Alone and with Cemiplimab for Advanced Solid Tumors — Sensei Biotherapeutics, Inc.
- Study on Using Tumor Infiltrating Lymphocytes for Treating Advanced Solid Cancers — Udai Kammula
- BLESSED: Expanded Access for DNG64 for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast — Aveni Foundation
- Program to Access Botensilimab and Balstilimab Before Official Approval — Agenus Inc.
- GALLANT: Study on Gemcitabine, Doxorubicin, Docetaxel, and Nivolumab for Advanced Sarcoma — Sarcoma Oncology Research Center, LLC
- Study on GI-101 Alone or with Pembrolizumab, Lenvatinib, or Local Radiotherapy for Advanced Solid Tumors — GI Innovation, Inc.
- Phase 1/2 Study of PEEL-224 with Vincristine and Temozolomide for Adolescents and Young Adults with Relapsed or Hard-to-Treat Sarcomas — David S Shulman, MD
- Study on Transarterial Chemoembolization for Treating Lung Cancer — City of Hope Medical Center
- Registry of Sarcoma Patients Treated with Permanent Low Dose Radiation CivaSheet® Implants — CivaTech Oncology
- Study on CBX-12 for Patients with Advanced or Metastatic Solid Tumors — Cybrexa Therapeutics
- Study on Talimogene Laherparepvec, Nivolumab, and Trabectedin for Treating Sarcoma — Sarcoma Oncology Research Center, LLC
- Study on Nivolumab After Partially Matched Bone Marrow Transplant in Children and Adults with Sarcoma — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Selumetinib and Bromodomain Inhibitor with Durvalumab for Treating Sarcomas — University of Alabama at Birmingham
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Sarcoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.